Welcome to our dedicated page for Bioharvest SEC filings (Ticker: BHST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioHarvest Sciences Inc. (BHST) disrupts biotechnology with its patented Botanical Synthesis platform—think yeast fermentation, but for whole-plant molecules. Investors scanning BioHarvest Sciences SEC filings want clarity on how nutraceutical sales and CDMO contracts convert breakthrough science into revenue, yet Form 10-K and 10-Q sections on R&D, scalability, and regulatory pathways can feel impenetrable.
Stock Titan delivers BioHarvest Sciences SEC filings explained simply. Our AI reads every line, then surfaces what matters: segment revenue shifts, patent portfolio updates, and consumption trends in cardiovascular health products found inside the BioHarvest Sciences annual report 10-K simplified. Need to track management moves? Receive BioHarvest Sciences Form 4 insider transactions real-time—no more manual EDGAR searches for BioHarvest Sciences insider trading Form 4 transactions.
Whether you’re researching a BioHarvest Sciences quarterly earnings report 10-Q filing, verifying BioHarvest Sciences proxy statement executive compensation, or parsing a sudden BioHarvest Sciences 8-K material events explained, the platform keeps you informed. Key features include:
- AI-powered summaries that translate dense disclosures into plain language, perfect for understanding BioHarvest Sciences SEC documents with AI.
- Real-time alerts the moment a BioHarvest Sciences executive stock transactions Form 4 posts.
- Unified access to every filing type—from R&D milestone 8-Ks to earnings report filing analysis—updated within seconds of EDGAR release.
Analysts use these insights to:
- Compare quarter-over-quarter nutraceutical margins
- Monitor insider buying ahead of new CDMO contracts
- Validate capital needs against large-scale bioreactor expansion
Skip the 200-page PDFs. Stock Titan’s AI-powered analysis distills BioHarvest Sciences disclosures into clear, decision-ready insights before the market opens.
BioHarvest Sciences Inc. (BHST) filed a Prospectus Supplement enabling the resale of up to 461,538 common shares by a selling shareholder. The company is not selling any securities and will not receive proceeds from these sales; the selling holder will receive all net proceeds, while the company covers registration expenses.
The registered shares were issued upon conversion of the holder’s Convertible Notes on September 19, 2025 at USD 6.50 per share. The selling shareholder may dispose of shares on Nasdaq or via private transactions at market, fixed, related, varying, or negotiated prices through ordinary brokerage transactions as described under Plan of Distribution.
BioHarvest’s common shares trade on Nasdaq under “BHST.” The last reported sale price was USD 12.03 on October 14, 2025. Company common shares to be outstanding after this offering are stated as 19,593,267.
BioHarvest Sciences Inc. filed a Form D reporting a Regulation D, Rule 506(b) exempt equity offering with total proceeds of $401,348, all of which have been sold and $0 remaining. The notice shows the first sale occurred on 2025-09-19 and reports 2 total investors, with a stated $0 in sales commissions and finders' fees. The issuer is a corporation organized in British Columbia, Canada and identifies multiple executive officers and directors at its Vancouver address. The offering was not conducted as part of a business combination, the issuer does not intend the offering to last more than one year, and no proceeds are disclosed as paid to officers, directors, or promoters.
BioHarvest Sciences Inc. (BHST) discloses an extensive set of business and financial risks in this prospectus supplement, emphasizing the company's negative operating cash flow and concerns about its ability to continue as a going concern. The filing lists the need for additional capital, reliance on key inputs and e-commerce channels (VINIA.com, VINIA.co.il and Amazon Marketplace), potential subscription volatility, regulatory and manufacturing compliance risks, clinical trial enrollment risks for nutraceutical/cosmeceutical products, intellectual property and patent expiration risks, possible dilution from future financings, and uncertainty about a liquid trading market for the common shares.
FAQ
What is the current stock price of Bioharvest (BHST)?
What is the market cap of Bioharvest (BHST)?
